Fig. 1

Inactivated COVID-19 vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer. A Levels of total antibodies against SARS-CoV-2 in LCs and HCs after the second and booster dose of inactivated vaccine. B Concentrations (BAU/mL) of IgG anti-RBD antibodies in LCs and HC subjects after the second and booster dose of inactivated vaccine. C Inhibition rates (%) of NAb against WT evaluated by SARS-CoV-2 surrogate virus neutralization test (sVNT) in LCs and HC subjects after the second and booster dose of inactivated vaccine. D Inhibition rates (%) of NAb against Omicron BA.4/5 evaluated by SARS-CoV-2 surrogate virus neutralization test (sVNT) in LCs and HC subjects after the second and booster dose of inactivated vaccine. E Correlative analyses between SARS-CoV-2-specific antibody and patient’s age: two-dose and booster vaccination. F Correlative analyses between SARS-CoV-2-specific antibody and patient’s therapy: two-dose and booster vaccination